Proton radiation therapy for chordomas and chondrosarcomas of the skull base

Citation
Eb. Hug et al., Proton radiation therapy for chordomas and chondrosarcomas of the skull base, J NEUROSURG, 91(3), 1999, pp. 432-439
Citations number
32
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
JOURNAL OF NEUROSURGERY
ISSN journal
00223085 → ACNP
Volume
91
Issue
3
Year of publication
1999
Pages
432 - 439
Database
ISI
SICI code
0022-3085(199909)91:3<432:PRTFCA>2.0.ZU;2-U
Abstract
Object. Local tumor control, patient survival, and treatment failure outcom es were analyzed to assess treatment efficacy in 58 patients in whom fracti onated proton radiation therapy (RT) was administered for skull base chordo mas and chondrosarcomas. Methods. Between March 1992 and January 1998, a total of 58 patients who co uld be evaluated were treated for skull base tumors, 33 for chordoma and 25 for chondrosarcoma. Following various surgical procedures, residual tumor was detected in 91% of patients; 59% demonstrated brainstem involvement. Ta rget dosages ranged from 64.8 and 79.2 (mean 70.7) Co Gy equivalent. The ra nge of follow up was 7 to 75 months (mean 33 months). In 10 patients (17%) the treatment failed locally, resulting in local contr ol rates of 92% (23 of 25 patients) for chondrosarcomas and 76% (25 of 33 p atients) for chordomas. Tumor volume and brainstem involvement influenced c ontrol rates. All tumors with volumes of 25 mi or less remained locally con trolled, compared with 56% of tumors larger than 25 mi (p = 0.02); 94% of p atients without brainstem involvement did not experience recurrence; in pat ients with brainstem involvement land dose reduction because of brainstem t olerance constraints) the authors achieved a tumor control rate of 53% (p = 0.04). Three patients died of their disease, and one died of intercurrent disease. Actuarial 5-year survival rates were 100% for patients with chondr osarcoma and 79% for patients with chordoma. Grade 3 and 4 late toxicities were observed in four patients (7%) and were symptomatic in three (5%). Conclusions. High-dose proton RT offers excellent chances of lasting tumor control and survival, with acceptable risks. In this series all small- and medium-sized tumors with no demonstrable brainstem involvement have been co ntrolled; all such patients are alive. Surgical debulking enhanced delivery of full tumoricidal doses, but even patients with large tumors and disease abutting crucial normal structures benefited.